Tirzepatide and semaglutide are the two most widely prescribed GLP-1-family drugs, and they're compared constantly, in medical literature, insurance policy, and casual conversation alike. Here's how they actually stack up.
Mechanism Difference
Semaglutide activates a single receptor, GLP-1. Tirzepatide activates two, GLP-1 and GIP, discussed in more depth in each drug's individual guide on this site. This mechanistic difference is the basis for most of the efficacy comparison between them.
Efficacy Comparison
Across their respective trial programs, SURMOUNT for tirzepatide and STEP for semaglutide, tirzepatide has generally shown somewhat greater average weight loss at comparable trial endpoints, and a head-to-head trial (SURMOUNT-5) directly comparing the two for weight management reported significantly greater weight loss with tirzepatide. It's worth noting individual response varies considerably regardless of which drug is used, and average trial differences don't guarantee a specific individual will respond better to one over the other.
Side Effect Comparison
Both share a broadly similar gastrointestinal side effect profile, nausea, diarrhea, vomiting, constipation, and both carry the same thyroid C-cell tumor boxed warning and MTC/MEN2 contraindication. Trial data hasn't shown a dramatically different overall tolerability profile between them, though individual patients sometimes report tolerating one better than the other for reasons not fully explained by trial averages alone.
Cost and Availability Differences
Availability, insurance coverage, and compounding status have shifted somewhat independently for each drug at different points, discussed in this site's news coverage of the GLP-1 shortage and insurance coverage, meaning practical accessibility sometimes matters as much as the efficacy comparison in an actual prescribing decision.
How Prescribers Typically Approach the Choice
Beyond trial averages, physicians typically weigh insurance coverage and cost, a patient's specific health history and contraindications, and sometimes simply which formulation a patient tolerates better after trying it, since individual response isn't fully predictable in advance.
The Bottom Line
Both drugs have deep trial evidence behind them, and current comparative data gives tirzepatide a modest average efficacy edge, but the right choice for a specific person depends on individual factors, cost, and coverage that a trial average alone can't fully capture, which is exactly why this remains a decision made with a physician rather than from a general comparison alone.
Switching Between the Two
Some patients do switch from one drug to the other, typically due to insurance coverage changes, tolerability issues, or a desire to try the drug with the modestly higher average efficacy in trials. There's limited formal trial data specifically on switching protocols between the two, so this transition is generally managed individually by a prescriber based on clinical judgment rather than a standardized, trial-established switching schedule.